Drug Table - Misc Agents Flashcards Preview

Pharm Drug Table > Drug Table - Misc Agents > Flashcards

Flashcards in Drug Table - Misc Agents Deck (76)
Loading flashcards...
1

Imatinib (Gleevac) Class

Tyrosine Kinase
inhibitor

2

Imatinib (Gleevac) Mechanism

Inhibits Abl kinase by binding where ATP
should go; also inhibits PDGFR and c-kit;
metabolized by cytochrome P450

3

Imatinib (Gleevac) Therapeutics

First line therapy for CML; also,
gastrointestinal tumor (GIST)

4

Imatinib (Gleevac) Imp Side effects

Nausea and vomiting, fluid
retention, muscle cramps,
arthralgia

5

Imatinib (Gleevac) Other side effects

Myelosuppression

6

Imatinib (Gleevac) Misc

Oral (1/day)

7

Gefitinib (Iressa) Class

Tyrosine Kinase
inhibitor

8

Gefitinib (Iressa) Mechanism

Inhibit epidermal growth factor receptor
(EGFR) tyrosine kinase

9

Gefitinib (Iressa) Therapeutics

Non-small lung cancer

10

Erlotinib (Tarceva) Class

Tyrosine Kinase
inhibitor

11

Erlotinib (Tarceva) Mechanism

Inhibit epidermal growth factor receptor
(EGFR) tyrosine kinase

12

Erlotinib (Tarceva) Therapeutics

Non-small lung cancer

13

Nilotinib (Tasigna) class

Tyrosine Kinase
inhibitor

14

Nilotinib (Tasigna) Mechanism

Inhibits Abl kinase

15

Nilotinib (Tasigna) Therapeutics

Imatinib-resistant CML

16

Nilotinib (Tasigna) Imp side effects

Myelosuppression

17

Nilotinib (Tasigna) other side effects

QT prolongation, hepatotoxicity,
electrolyte abnormalities

18

Nilotinib (Tasigna) misc

Oral (2/day)

19

Dasatinib (Sprycel) class

Tyrosine Kinase
inhibitor

20

Dasatinib (Sprycel) mechanism

Inhibits Abl & Src kinases

21

Dasatinib (Sprycel) therapeutics

Imatinib-resistant CML

22

Dasatinib (Sprycel) Imp side effects

Myelosuppression, bleeding, fluid
retention, pulmonary arterial
hypertension

23

Dasatinib (Sprycel) other side effects

Diarrhea, nausea and vomiting,
weakness, infections

24

Dasatinib (Sprycel) misc

Oral (1/day)

25

Rituximab (Rituxan) class

Monoclonal
antibody

26

Rituximab (Rituxan) mechanism

CD20 B-cell antibody that can directly
activate apoptosis, activate complement, or
activate cell-mediated cytotoxicity (e.g., T
cells, NK cells)

27

Rituximab (Rituxan) therapeutics

Non-Hodgkin's lymphomas

28

Rituximab (Rituxan) imp side effects

Infusion reactions, tumor lysis
syndrome (TLS), severe
mucocutaneous reactions,
progressive multifocal
leukoencephalopathy (PML)

29

Rituximab (Rituxan) other side effects

Skin reactions, irregular
heartbeat, muscle or joint pain

30

Rituximab (Rituxan) misc

Patients need careful monitoring

31

Trastuzumab (Herceptin) class

Monoclonal
antibody

32

Trastuzumab (Herceptin) mechanism

Unknown HER2/neu (ErbB2) receptor
antibody mechanism (enhanced receptor
endocytosis or blocking homo- or
heterodimerization)

33

Trastuzumab (Herceptin) therapeutics

HER2/neu-overexpressing metastatic
breast cancer

34

Trastuzumab (Herceptin) Imp side effects

Hypersentivity reaction; ventricular
dysfunction

35

Trastuzumab (Herceptin) misc

Usually combined with taxanes;
enhances doxorubicin cardiotoxicity

36

Cetuximab (Erbitux) class

Monoclonal
antibody

37

Cetuximab (Erbitux) mechanism

EGFR1 (ErbB1)

38

Cetuximab (Erbitux) therapeutics

EGFR-positive metastatic colorectal
cancer

39

Cetuximab (Erbitux) imp side effects

Allergic reactions, sudden cardiac
death, dermatologic problems,
infections, renal failure, electrolyte
abnormalities

40

Cetuximab (Erbitux) other side effects

Asthenia/malaise, fever,
nausea, constipation, interstitial
pneumonitis

41

Cetuximab (Erbitux) misc

Clinical trials, probably combine with
cisplatin

42

Cetuximab (Erbitux) class

Monoclonal
antibody

43

Cetuximab (Erbitux) mechanism

EGFR1 (ErbB1)

44

Cetuximab (Erbitux) therapeutics

EGFR-positive metastatic colorectal
cancer

45

Cetuximab (Erbitux) imp side effects

Allergic reactions, sudden cardiac
death, dermatologic problems,
infections, renal failure, electrolyte
abnormalities

46

Cetuximab (Erbitux) other side effects

Asthenia/malaise, fever,
nausea, constipation, interstitial
pneumonitis

47

Cetuximab (Erbitux) misc

Clinical trials, probably combine with
cisplatin

48

Ipilimumab (Yervoy) class

Human
monoclonal
antibody

49

Ipilimumab (Yervoy) mechanism

Cytotoxic T-Lymphocyte Antigen 4 inhibitor;
stimulates immune system

50

Ipilimumab (Yervoy) therapeutics

Melanoma

51

Vemurafenib (Zelboraf) class

Serine/threonine
kinase inhibitor

52

Vemurafenib (Zelboraf) mechanism

Inhibits oncogenic BRAF kinase

53

Vemurafenib (Zelboraf) therapeutics

Unresectable Stage III and IV or
metastatic melanomas w/BRAF
mutations

54

Vemurafenib (Zelboraf) imp side effects

Arthralgia, fatigue, photosensitivity,
nausea, alopecia, diarrhea, QT
prolongation

55

Vemurafenib (Zelboraf) other side effects

Cutaneous squamous cell
carcinoma, keratoacanthoma,
new primary cutaneous
melanoma

56

Vemurafenib (Zelboraf) misc

Superior to dacarbazine in Phase III
trials

57

Dabrafenib (Tafinlar) class

Serine/threonine
kinase inhibitor

58

Dabrafenib (Tafinlar) mechanism

Inhibits oncogenic BRAF kinase

59

Dabrafenib (Tafinlar) therapeutics

Unresectable Stage III and IV or
metastatic melanomas w/BRAF
mutations

60

Dabrafenib (Tafinlar) imp side effects

Serious febrile drug reactions,
uveitis and iritis, hyperglycemia,
hyperkeratosis

61

Dabrafenib (Tafinlar) other side effects

Higher risk of developing:
Serious febrile drug reactions,
uveitis and iritis, hyperglycemia,
hyperkeratosis

62

Dabrafenib (Tafinlar) misc

May cause male infertility

63

Trametinib (Mekinist) mechanism

Inhibits MEK

64

Trametinib (Mekinist) therapeutics

Unresectable Stage III and IV or
metastatic melanomas w/BRAF
mutations

65

Trametinib (Mekinist) imp side effects

Cardiomyopathy, retinal disorders,
interstitial lung disease, serious
skin toxicities

66

Trametinib (Mekinist) other side effects

Rash, diarrhea, stomatitis,
hypertension, pruritis

67

Trametinib (Mekinist) misc

May cause female infertility

68

Hydroxyurea (Hydrea) mechanism

Inhibits ribonucleoside diphosphate
reductase

69

Hydroxyurea (Hydrea) therapeutics

CML (replaced by Imatinib),
polycythemia vera, essential
thrombocythemia; treatment for sickle
cell disease (increases Hb-F)

70

Retinoids Mechanism

ATRA induces terminal differentiation in
malignant immature promyelocytes, which
subsequently apoptose

71

Retinoids Therapeutics

APL

72

Retinoids imp side effects

"Leukocyte Activation Syndrome"
(LAS), an increase in WBCs (fever,
weight gain, respiratory distress,
serosal effusion, renal failure)

73

Retinoids misc

Combined w/anthracyclines;
corticosteroids used to block "LAS"

74

Arsenic Trioxide (Trisenox) Therapeutics

Relapsed APL

75

Thalidomide (Thalomid) Therapeutics

Multiple myeloma and myelodysplastic
syndromes

76

Interferons

Hairy-cell leukemia, CML, and AIDSrelated
Kaposi's sarcoma